학술논문
LBA44 Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial
Document Type
Abstract
Author
Source
In Annals of Oncology September 2022 33 Supplement 7:S1410-S1411
Subject
Language
ISSN
0923-7534